Press Releases Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 09:05:12 05/06/2026 pm IST			5-day change	1st Jan Change
36.16 ^EUR	+1.69%		-1.01%	-2.30%

05/06	Study: Bayer's Finerenone slows progression of chronic kidney disease	RE
05/06	Bayer Announces Phase III FIND-CKD Results For KERENDIA In Non-Diabetic Chronic Kidney Disease	CI

Press Releases

05/06	Bayer : Finerenone significantly reduced the risk of kidney disease progression and cardiovascular outcomes in broad patient populations with CKD	PU
05/06	Bayer : finerenone significantly reduced kidney function decline and a composite of cardiovascular-kidney outcomes versus placebo in patients with non-diabetic chronic kidney disease	PU
05/06	Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease	BU
02/06	Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026	BU
31/05	ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial	BU
22/05	Bayer : Kerendia™ approved in China for new indication in adult patients with heart failure with LVEF ≥40%	PU
21/05	ASCO 2026: Bayer to Present New Data Across Oncology Portfolio	BU
21/05	Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease	BU
19/05	Bayer : New drug applications for asundexian accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare	PU
19/05	Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack	BU
18/05	U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer	BU
18/05	Bayer : FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer	PU
15/05	AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer	BU
15/05	Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement	BU
13/05	Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities	BU
12/05	Bayer : Q1 Media Update	PU
12/05	Bayer : First Quarter 2026 Results and Media Update	PU
12/05	Bayer : Quarterly Statement First Quarter 2026	PU
12/05	Bayer : reports solid start to the year and confirms currency-adjusted Group guidance for 2026	PU
07/05	Bayer and bp Form Strategic Alliance to Jointly Scale Camelina as Intermediate Crop for Biofuels	AQ
07/05	Bayer : China’s Center of Drug Evaluation grants Priority Review designation for Bayer’s FXIa inhibitor	PU
07/05	Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis	BU
06/05	Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline	BU
30/04	Bayer - New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing	AQ
29/04	New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing	BU